- Home
- OVID vs PYPD Comparison
OVID vs PYPD Comparison
Compare OVID & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVID
- PYPD
- Stock Information
- Founded
- OVID 2014
- PYPD 2008
- Country
- OVID United States
- PYPD Israel
- Employees
- OVID N/A
- PYPD N/A
- Industry
- OVID Biotechnology: Pharmaceutical Preparations
- PYPD Medical/Dental Instruments
- Sector
- OVID Health Care
- PYPD Health Care
- Exchange
- OVID Nasdaq
- PYPD Nasdaq
- Market Cap
- OVID 24.0M
- PYPD 26.7M
- IPO Year
- OVID 2017
- PYPD 2020
- Fundamental
- Price
- OVID $0.29
- PYPD $2.77
- Analyst Decision
- OVID Strong Buy
- PYPD Strong Buy
- Analyst Count
- OVID 6
- PYPD 2
- Target Price
- OVID $3.03
- PYPD $10.50
- AVG Volume (30 Days)
- OVID 376.8K
- PYPD 15.1K
- Earning Date
- OVID 05-20-2025
- PYPD 05-14-2025
- Dividend Yield
- OVID N/A
- PYPD N/A
- EPS Growth
- OVID N/A
- PYPD N/A
- EPS
- OVID N/A
- PYPD N/A
- Revenue
- OVID $566,000.00
- PYPD N/A
- Revenue This Year
- OVID N/A
- PYPD N/A
- Revenue Next Year
- OVID $36.11
- PYPD N/A
- P/E Ratio
- OVID N/A
- PYPD N/A
- Revenue Growth
- OVID 44.39
- PYPD N/A
- 52 Week Low
- OVID $0.24
- PYPD $2.30
- 52 Week High
- OVID $3.43
- PYPD $4.75
- Technical
- Relative Strength Index (RSI)
- OVID 39.90
- PYPD 52.30
- Support Level
- OVID $0.28
- PYPD $2.71
- Resistance Level
- OVID $0.33
- PYPD $2.89
- Average True Range (ATR)
- OVID 0.03
- PYPD 0.15
- MACD
- OVID 0.00
- PYPD 0.02
- Stochastic Oscillator
- OVID 16.97
- PYPD 40.00
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.